FOOTHILL RANCH, Calif.--(BUSINESS WIRE)--TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the successful installation of its neutron beam system at Xiamen Humanity Hospital, the most advanced accelerator-based BNCT facility in Greater China, newly built in partnership with Neuboron Medical Group.
TLS’ Neutron Beam System enables a new treatment modality for patients diagnosed with the most aggressive and recurrent cancers such as gliomas, head and neck tumors, and melanomas, by delivering more precise, targeted radiation to cancer cells while sparing damage to surrounding healthy tissue. This technique holds promise in treating patients with cancer for whom other treatment options have been exhausted or are unavailable.
“The installation of our NBS at Xiamen Humanity Hospital represents a tremendous milestone in our mission to improve the lives of people diagnosed with invasive, recurrent and difficult to treat cancers,” said Bruce Bauer, Chief Executive Officer of TAE Life Sciences. “TAE Life Sciences is also developing comprehensive boron target drugs and a neutron technology product portfolio to enable BNCT as a new cancer treatment modality for patients globally. With the global pandemic challenging our installation plans along with restrictions in travel, this milestone is even more meaningful, and we want to thank our colleagues at Xiamen Humanity Hospital and our partner in China, Neuboron, for all of their efforts in helping to make this possible.”
Accelerating New Hope in the Fight Against Cancer: Presentations at ICNCT19
Committed to developing a new generation of targeted radiotherapy for patients with cancer, TAE Life Sciences will present 5 oral presentations at the19th International Congress on Neutron Capture Therapy (ICNCT19) on BNCT, occurring virtually September 27 – October 1, 2021.
- Product and Facility Design Optimization for an Accelerator BNCT Building Expansion Project in Pavia, Italy
- Development of new small molecule drugs for Boron Neutron Capture Therapy
- Target selection and development of antibody boron conjugates for boron neutron capture therapy of head and neck cancer
- Application of high fidelity radiation transport models to facility design, material selection, and shielding concepts for p-7Li accelerator based BNCT
- Architecture, Implementation and First Performance Results of a Neutron Beam System for Accelerator BNCT
In addition, TLS’s partner for China, Neuboron, will be presenting an update on the design and installation of the BNCT facility at Xiamen Humanity Hospital.
For presentation details, visit: http://www.icnct19.org/.
About Biologically Targeted Radiation Therapy (BNCT)
BNCT is a non-invasive, biologically targeted particle therapy that combines a non-toxic compound containing boron-10 and a low-energy, epithermal neutron beam. This combination generates a therapeutic dose at the cellular level that destroys tumor cells while sparing healthy tissues surrounding the tumor. This results in less toxicity for the patient and the potential to escalate the therapeutic dose to the cancer cells. BNCT has the potential to treat undetected metastases in the local region of the tumor in the same treatment session, which is difficult to impossible for conventional radiotherapy because of the logistical patient treatment setup barriers and the amount of radiation that would be delivered to healthy cells. In addition, BNCT may be utilized for several cancers which are resistant to many, if not all, current cancer therapies available, such as glioblastoma multiforme.
About TAE Life Sciences
TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy accelerator-based neutron source – optimized for an in-hospital BNCT program that can one day treat patients with the most aggressive and recurrent cancers. We have assembled a world-class, cross-functional team of clinicians, radiation oncologists, physicists, and other researchers to enable us to bring our technology to cancer patients who need it most. TLS’s target drugs and neutron radiation system are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at www.taelifesciences.com.
